Global Viral Vector Manufacturing Market – Industry Analysis and Forecast (2019-2026) – By Type, Disease, Application, and Region.

Global Viral Vector Manufacturing Market was valued US$ 384.82 Mn in 2019 and is expected to reach US$ XX Mn by 2026, at a CAGR of XX % during a forecast period. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region. To know about the Research Methodology:-Request Free Sample Report

Global Viral Vector Manufacturing Market Dynamics:

The viral vector manufacturing market is segmented into type, disease, application, and region. In terms of Type, the global viral vector manufacturing market is classified into retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors. Based on the disease, the global viral vector manufacturing market is divided into cancers, genetic disorders, infectious diseases, and other diseases. Further, by application it is bifurcated into gene therapy and vaccinology. Based on regions, the global viral vector manufacturing market is divided into five main regions- North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Based on a disease, the cancer is expected to account for the largest share of the global market due to the growing research on viral vector gene therapies for cancer. On the basis of type, the retroviral vectors segment dominated the global viral vectors manufacturing market due to ease of application in major target diseases such as cancer and genetic disorders. By application, the gene therapy segment is expected to grow at the highest rate during the forecast period due to the availability of effective viral vector gene therapies for rare diseases and cancers, ongoing research activities on viral vector gene therapies, and the recent approval of several viral vector gene therapies are driving the growth of this market. In terms of end users, the pharmaceutical and biopharmaceutical companies are expected to account for the XX% share of the global market during the forecast period owing to the successful launch of viral vector gene therapies and a robust pipeline. The major driving factor of the global viral vector manufacturing market is rising prevalence of genetic disorders, cancer, and infectious diseases, availability of funding for the development of gene therapy, and effectiveness of viral vectors. Additionally, ongoing research into viral vector-based gene and cell therapies is also boosting the market growth. High costs associated with gene therapy and short shelf-life of viral vectors are hampering the growth of the global viral vector manufacturing market. Risk of mutagenesis and other unwanted outcomes is the major challenge of the market. Geographically, Asia Pacific is expected to grow at the fastest rate viral vector manufacturing market during the forecast period due to the growing research activities to launch novel gene therapies in the untapped market of this region.

Global Viral Vector Manufacturing Market, Key Highlights:

• Global Viral Vector Manufacturing Market analysis and forecast, in terms of value. • Comprehensive study and analysis of market drivers, restraints and opportunities influencing the growth of the Global Viral Vector Manufacturing Market • Global Viral Vector Manufacturing Market segmentation on the basis of type, source, end-user, and region (country-wise) has been provided. • Global Viral Vector Manufacturing Market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of study. • Global Viral Vector Manufacturing Market analysis and forecast for five major regions namely North America, Europe, Asia Pacific, the Middle East & Africa (MEA) and Latin America along with country-wise segmentation. • Profiles of key industry players, their strategic perspective, market positioning and analysis of core competencies are further profiled. • Competitive developments, investments, strategic expansion and competitive landscape of the key players operating in the Global Viral Vector Manufacturing Market are also profiled.

Scope of Global Viral Vector Manufacturing Market: Inquire before buying

Global Viral Vector Manufacturing Market, by Type:

• Retroviral Vectors • Adenoviral Vectors • Adeno-associated Viral Vectors • Other Viral Vectors

Global Viral Vector Manufacturing Market, by Disease:

• Cancers • Genetic Disorders • Infectious diseases • Other Diseases

Global Viral Vector Manufacturing Market, by Application:

• Gene Therapy • Vaccinology

Global Viral Vector Manufacturing Market, by Region:

• North America • Europe • Middle East & Africa • Asia Pacific • Latin America

Global Viral Vector Manufacturing Market Key Players :

• Advanced Bioscience Laboratories, Inc. • Advanced Biotherapeutics Consulting • Applied Viromics • Batavia Biosciences • Benitec Biopharma • Biogen Idec (Now Biogen, Inc.) • Biovian • Boehringer Ingelheim Gmbh • Brammer Bio • Cell and Gene Therapy Catapult • Ceva Corporate • Cobra Biologics (Subsidiary of Recip Ab) • Creative Biogene • GE Healthcare • Genedetect • Genvec Inc. (Subsidiary of Intrexon Corp.) • ID Pharma Co. Ltd. • Janssen Pharmaceutical Companies of Johnson & Johnson • Lonza • Merck Millipore • Miltenyi Biotec • Molmed Spa • Paragon Bioservices Inc. • Pfizer Inc. • Sanofi • Sementis • Spark Therapeutics Inc. • Synpromics • Valneva • Vector Biolabs • Vigene Biosciences Inc. • Virovek

Global Viral Vector Manufacturing Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 1.4. Key Questions Answered 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations Used 2.3. Research Methodology 3. Executive Summary 3.1. Global Viral Vector Manufacturing Markets Size, by Market Value (US$ Mn) and Market, by Region 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.3. Drivers and Restraints Snapshot Analysis 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.3.4. Porter’s Analysis 4.3.5. Value Chain Analysis 4.3.6. SWOT Analysis 4.4. Global Viral Vector Manufacturing Market Industry Trends and Emerging Technologies 5. Global Viral Vector Manufacturing Markets Analysis and Forecast 5.1. Global Viral Vector Manufacturing Markets Analysis and Forecast 5.2. Global Viral Vector Manufacturing Markets Size& Y-o-Y Growth Analysis 5.2.1. North America 5.2.2. Europe 5.2.3. Asia Pacific 5.2.4. Middle East & Africa 5.2.5. Latin America 6. Global Viral Vector Manufacturing Markets Analysis and Forecast, by Type 6.1. Introduction and Definition 6.2. Key Findings 6.3. Global Viral Vector Manufacturing Markets Value Share Analysis, by Type 6.4. Global Viral Vector Manufacturing Markets Size (US$ Mn) Forecast, by Type 6.5. Global Viral Vector Manufacturing Markets Analysis, by Type 6.6. Global Viral Vector Manufacturing Markets Attractiveness Analysis, by Type 7. Global Viral Vector Manufacturing Markets Analysis and Forecast, by Disease 7.1. Introduction and Definition 7.2. Global Viral Vector Manufacturing Markets Value Share Analysis, by Disease 7.3. Global Viral Vector Manufacturing Markets Size (US$ Mn) Forecast, by Disease 7.4. Global Viral Vector Manufacturing Markets Analysis, by Disease 7.5. Global Viral Vector Manufacturing Markets Attractiveness Analysis, by Disease 8. Global Viral Vector Manufacturing Markets Analysis and Forecast, by Application 8.1. Introduction and Definition 8.2. Global Viral Vector Manufacturing Markets Value Share Analysis, by Application 8.3. Global Viral Vector Manufacturing Markets Size (US$ Mn) Forecast, by Application 8.4. Global Viral Vector Manufacturing Markets Analysis, by Application 8.5. Global Viral Vector Manufacturing Markets Attractiveness Analysis, by Application 9. Global Viral Vector Manufacturing Markets Analysis, by Region 9.1. Global Viral Vector Manufacturing Markets Value Share Analysis, by Region 9.2. Global Viral Vector Manufacturing Markets Size (US$ Mn) Forecast, by Region 9.3. Global Viral Vector Manufacturing Markets Attractiveness Analysis, by Region 10. North America Viral Vector Manufacturing Markets Analysis 10.1. Key Findings 10.2. North America Viral Vector Manufacturing Markets Overview 10.3. North America Viral Vector Manufacturing Markets Value Share Analysis, by Type 10.4. North America Viral Vector Manufacturing Markets Forecast, by Type 10.4.1. Retroviral Vectors 10.4.2. Adenoviral Vectors 10.4.3. Adeno-associated Viral Vectors 10.4.4. Other Viral Vectors 10.5. North America Viral Vector Manufacturing Markets Value Share Analysis, by Disease 10.6. North America Viral Vector Manufacturing Markets Forecast, by Disease 10.6.1. Cancers 10.6.2. Genetic Disorders 10.6.3. Infectious diseases 10.6.4. Other Diseases 10.7. North America Viral Vector Manufacturing Markets Value Share Analysis, by Application 10.8. North America Viral Vector Manufacturing Markets Forecast, by Application 10.8.1. Gene Therapy 10.8.2. Vaccinology 10.8.3. Others 10.9. North America Viral Vector Manufacturing Markets Value Share Analysis, by Country 10.10. North America Viral Vector Manufacturing Markets Forecast, by Country 10.10.1. U.S. 10.10.2. Canada 10.11. North America Viral Vector Manufacturing Markets Analysis, by Country 10.12. U.S. Viral Vector Manufacturing Markets Forecast, by Type 10.12.1. Retroviral Vectors 10.12.2. Adenoviral Vectors 10.12.3. Adeno-associated Viral Vectors 10.12.4. Other Viral Vectors 10.13. U.S. Viral Vector Manufacturing Markets Forecast, by Disease 10.13.1. Cancers 10.13.2. Genetic Disorders 10.13.3. Infectious diseases 10.13.4. Other Diseases 10.14. U.S. Viral Vector Manufacturing Markets Forecast, by Application 10.14.1. Gene Therapy 10.14.2. Vaccinology 10.14.3. Others 10.15. Canada Viral Vector Manufacturing Markets Forecast, by Type 10.15.1. Retroviral Vectors 10.15.2. Adenoviral Vectors 10.15.3. Adeno-associated Viral Vectors 10.15.4. Other Viral Vectors 10.16. Canada Viral Vector Manufacturing Markets Forecast, by Disease 10.16.1. Cancers 10.16.2. Genetic Disorders 10.16.3. Infectious diseases 10.16.4. Other Diseases 10.17. Canada Viral Vector Manufacturing Markets Forecast, by Application 10.17.1. Gene Therapy 10.17.2. Vaccinology 10.17.3. Others 10.18. North America Viral Vector Manufacturing Markets Attractiveness Analysis 10.18.1. By Type 10.18.2. By Disease 10.18.3. By Application 10.19. PEST Analysis 11. Europe Viral Vector Manufacturing Markets Analysis 11.1. Key Findings 11.2. Europe Viral Vector Manufacturing Markets Overview 11.3. Europe Viral Vector Manufacturing Markets Value Share Analysis, by Type 11.4. Europe Viral Vector Manufacturing Markets Forecast, by Type 11.4.1. Retroviral Vectors 11.4.2. Adenoviral Vectors 11.4.3. Adeno-associated Viral Vectors 11.4.4. Other Viral Vectors 11.5. Europe Viral Vector Manufacturing Markets Value Share Analysis, by Disease 11.6. Europe Viral Vector Manufacturing Markets Forecast, by Disease 11.6.1. Cancers 11.6.2. Genetic Disorders 11.6.3. Infectious diseases 11.6.4. Other Diseases 11.7. Europe Viral Vector Manufacturing Markets Value Share Analysis, by Application 11.8. Europe Viral Vector Manufacturing Markets Forecast, by Application 11.8.1. Gene Therapy 11.8.2. Vaccinology 11.8.3. Others 11.9. Europe Viral Vector Manufacturing Markets Value Share Analysis, by Country 11.10. Europe Viral Vector Manufacturing Markets Forecast, by Country 11.10.1. Germany 11.10.2. U.K. 11.10.3. France 11.10.4. Italy 11.10.5. Spain 11.10.6. Rest of Europe 11.11. Europe Viral Vector Manufacturing Markets Analysis, by Country/ Sub-region 11.12. Germany Viral Vector Manufacturing Markets Forecast, by Type 11.12.1. Retroviral Vectors 11.12.2. Adenoviral Vectors 11.12.3. Adeno-associated Viral Vectors 11.12.4. Other Viral Vectors 11.13. Germany Viral Vector Manufacturing Markets Forecast, by Disease 11.13.1. Cancers 11.13.2. Genetic Disorders 11.13.3. Infectious diseases 11.13.4. Other Diseases 11.14. Germany Viral Vector Manufacturing Markets Forecast, by Application 11.14.1. Gene Therapy 11.14.2. Vaccinology 11.14.3. Others 11.15. U.K. Viral Vector Manufacturing Markets Forecast, by Type 11.15.1. Retroviral Vectors 11.15.2. Adenoviral Vectors 11.15.3. Adeno-associated Viral Vectors 11.15.4. Other Viral Vectors 11.16. U.K. Viral Vector Manufacturing Markets Forecast, by Disease 11.16.1. Cancers 11.16.2. Genetic Disorders 11.16.3. Infectious diseases 11.16.4. Other Diseases 11.17. U.K. Viral Vector Manufacturing Markets Forecast, by Application 11.17.1. Gene Therapy 11.17.2. Vaccinology 11.17.3. Others 11.18. France Viral Vector Manufacturing Markets Forecast, by Type 11.18.1. Retroviral Vectors 11.18.2. Adenoviral Vectors 11.18.3. Adeno-associated Viral Vectors 11.18.4. Other Viral Vectors 11.19. France Viral Vector Manufacturing Markets Forecast, by Disease 11.19.1. Cancers 11.19.2. Genetic Disorders 11.19.3. Infectious diseases 11.19.4. Other Diseases 11.20. France Viral Vector Manufacturing Markets Forecast, by Application 11.20.1. Gene Therapy 11.20.2. Vaccinology 11.20.3. Others 11.21. Italy Viral Vector Manufacturing Markets Forecast, by Type 11.21.1. Retroviral Vectors 11.21.2. Adenoviral Vectors 11.21.3. Adeno-associated Viral Vectors 11.21.4. Other Viral Vectors 11.22. Italy Viral Vector Manufacturing Markets Forecast, by Disease 11.22.1. Cancers 11.22.2. Genetic Disorders 11.22.3. Infectious diseases 11.22.4. Other Diseases 11.23. Italy Viral Vector Manufacturing Markets Forecast, by Application 11.23.1. Gene Therapy 11.23.2. Vaccinology 11.23.3. Others 11.24. Spain Viral Vector Manufacturing Markets Forecast, by Type 11.24.1. Retroviral Vectors 11.24.2. Adenoviral Vectors 11.24.3. Adeno-associated Viral Vectors 11.24.4. Other Viral Vectors 11.25. Spain Viral Vector Manufacturing Markets Forecast, by Disease 11.25.1. Cancers 11.25.2. Genetic Disorders 11.25.3. Infectious diseases 11.25.4. Other Diseases 11.26. Spain Viral Vector Manufacturing Markets Forecast, by Application 11.26.1. Gene Therapy 11.26.2. Vaccinology 11.26.3. Others 11.27. Rest of Europe Viral Vector Manufacturing Markets Forecast, by Type 11.27.1. Retroviral Vectors 11.27.2. Adenoviral Vectors 11.27.3. Adeno-associated Viral Vectors 11.27.4. Other Viral Vectors 11.27.5. 11.28. Rest of Europe Viral Vector Manufacturing Markets Forecast, by Disease 11.28.1. Cancers 11.28.2. Genetic Disorders 11.28.3. Infectious diseases 11.28.4. Other Diseases 11.29. Rest of Europe Viral Vector Manufacturing Markets Forecast, by Application 11.29.1. Gene Therapy 11.29.2. Vaccinology 11.29.3. Others 11.30. Europe Viral Vector Manufacturing Markets Attractiveness Analysis 11.30.1. By Type 11.30.2. By Disease 11.30.3. By Application 11.31. PEST Analysis 12. Asia Pacific Viral Vector Manufacturing Markets Analysis 12.1. Key Findings 12.2. Asia Pacific Viral Vector Manufacturing Markets Overview 12.3. Asia Pacific Viral Vector Manufacturing Markets Value Share Analysis, by Type 12.4. Asia Pacific Viral Vector Manufacturing Markets Forecast, by Type 12.4.1. Retroviral Vectors 12.4.2. Adenoviral Vectors 12.4.3. Adeno-associated Viral Vectors 12.4.4. Other Viral Vectors 12.4.5. 12.5. Asia Pacific Viral Vector Manufacturing Markets Value Share Analysis, by Disease 12.6. Asia Pacific Viral Vector Manufacturing Markets Forecast, by Disease 12.6.1. Cancers 12.6.2. Genetic Disorders 12.6.3. Infectious diseases 12.6.4. Other Diseases 12.7. Asia Pacific Viral Vector Manufacturing Markets Value Share Analysis, by Application 12.8. Asia Pacific Viral Vector Manufacturing Markets Forecast, by Application 12.8.1. Gene Therapy 12.8.2. Vaccinology 12.8.3. Others 12.9. Asia Pacific Viral Vector Manufacturing Markets Value Share Analysis, by Country 12.10. Asia Pacific Viral Vector Manufacturing Markets Forecast, by Country 12.10.1. China 12.10.2. India 12.10.3. Japan 12.10.4. ASEAN 12.10.5. Rest of Asia Pacific 12.11. Asia Pacific Viral Vector Manufacturing Markets Analysis, by Country/ Sub-region 12.12. China Viral Vector Manufacturing Markets Forecast, by Type 12.12.1. Retroviral Vectors 12.12.2. Adenoviral Vectors 12.12.3. Adeno-associated Viral Vectors 12.12.4. Other Viral Vectors 12.12.5. 12.13. China Viral Vector Manufacturing Markets Forecast, by Disease 12.13.1. Cancers 12.13.2. Genetic Disorders 12.13.3. Infectious diseases 12.13.4. Other Diseases 12.14. China Viral Vector Manufacturing Markets Forecast, by Application 12.14.1. Gene Therapy 12.14.2. Vaccinology 12.14.3. Others 12.15. India Viral Vector Manufacturing Markets Forecast, by Type 12.15.1. Retroviral Vectors 12.15.2. Adenoviral Vectors 12.15.3. Adeno-associated Viral Vectors 12.15.4. Other Viral Vectors 12.16. India Viral Vector Manufacturing Markets Forecast, by Disease 12.16.1. Cancers 12.16.2. Genetic Disorders 12.16.3. Infectious diseases 12.16.4. Other Diseases 12.17. India Viral Vector Manufacturing Markets Forecast, by Application 12.17.1. Gene Therapy 12.17.2. Vaccinology 12.17.3. Others 12.18. Japan Viral Vector Manufacturing Markets Forecast, by Type 12.18.1. Retroviral Vectors 12.18.2. Adenoviral Vectors 12.18.3. Adeno-associated Viral Vectors 12.18.4. Other Viral Vectors 12.19. Japan Viral Vector Manufacturing Markets Forecast, by Disease 12.19.1. Cancers 12.19.2. Genetic Disorders 12.19.3. Infectious diseases 12.19.4. Other Diseases 12.20. Japan Viral Vector Manufacturing Markets Forecast, by Application 12.20.1. Gene Therapy 12.20.2. Vaccinology 12.20.3. Others 12.21. ASEAN Viral Vector Manufacturing Markets Forecast, by Type 12.21.1. Retroviral Vectors 12.21.2. Adenoviral Vectors 12.21.3. Adeno-associated Viral Vectors 12.21.4. Other Viral Vectors 12.22. ASEAN Viral Vector Manufacturing Markets Forecast, by Disease 12.22.1. Cancers 12.22.2. Genetic Disorders 12.22.3. Infectious diseases 12.22.4. Other Diseases 12.23. ASEAN Viral Vector Manufacturing Markets Forecast, by Application 12.23.1. Gene Therapy 12.23.2. Vaccinology 12.23.3. Others 12.24. Rest of Asia Pacific Viral Vector Manufacturing Markets Forecast, by Type 12.24.1. Retroviral Vectors 12.24.2. Adenoviral Vectors 12.24.3. Adeno-associated Viral Vectors 12.24.4. Other Viral Vectors 12.25. Rest of Asia Pacific Viral Vector Manufacturing Markets Forecast, by Disease 12.25.1. Cancers 12.25.2. Genetic Disorders 12.25.3. Infectious diseases 12.25.4. Other Diseases 12.26. Rest of Asia Pacific Viral Vector Manufacturing Markets Forecast, by Application 12.26.1. Gene Therapy 12.26.2. Vaccinology 12.26.3. Others 12.27. Asia Pacific Viral Vector Manufacturing Markets Attractiveness Analysis 12.27.1. By Type 12.27.2. By Disease 12.27.3. By Application 12.28. PEST Analysis 13. Middle East & Africa Viral Vector Manufacturing Markets Analysis 13.1. Key Findings 13.2. Middle East & Africa Viral Vector Manufacturing Markets Overview 13.3. Middle East & Africa Viral Vector Manufacturing Markets Value Share Analysis, by Type 13.4. Middle East & Africa Viral Vector Manufacturing Markets Forecast, by Type 13.4.1. Retroviral Vectors 13.4.2. Adenoviral Vectors 13.4.3. Adeno-associated Viral Vectors 13.4.4. Other Viral Vectors 13.5. Middle East & Africa Viral Vector Manufacturing Markets Value Share Analysis, by Disease 13.6. Middle East & Africa Viral Vector Manufacturing Markets Forecast, by Disease 13.6.1. Cancers 13.6.2. Genetic Disorders 13.6.3. Infectious diseases 13.6.4. Other Diseases 13.7. Middle East & Africa Viral Vector Manufacturing Markets Value Share Analysis, by Application 13.8. Middle East & Africa Viral Vector Manufacturing Markets Forecast, by Application 13.8.1. Gene Therapy 13.8.2. Vaccinology 13.8.3. Others 13.9. Middle East & Africa Viral Vector Manufacturing Markets Value Share Analysis, by Country 13.10. Middle East & Africa Viral Vector Manufacturing Markets Forecast, by Country 13.10.1. GCC 13.10.2. South Africa 13.10.3. Rest of Middle East & Africa 13.11. Middle East & Africa Viral Vector Manufacturing Markets Analysis, by Country/ Sub-region 13.12. GCC Viral Vector Manufacturing Markets Forecast, by Type 13.12.1. Retroviral Vectors 13.12.2. Adenoviral Vectors 13.12.3. Adeno-associated Viral Vectors 13.12.4. Other Viral Vectors 13.13. GCC Viral Vector Manufacturing Markets Forecast, by Disease 13.13.1. Cancers 13.13.2. Genetic Disorders 13.13.3. Infectious diseases 13.13.4. Other Diseases 13.14. GCC Viral Vector Manufacturing Markets Forecast, by Application 13.14.1. Gene Therapy 13.14.2. Vaccinology 13.14.3. Others 13.15. South Africa Viral Vector Manufacturing Markets Forecast, by Type 13.15.1. Retroviral Vectors 13.15.2. Adenoviral Vectors 13.15.3. Adeno-associated Viral Vectors 13.15.4. Other Viral Vectors 13.16. South Africa Viral Vector Manufacturing Markets Forecast, by Disease 13.16.1. Cancers 13.16.2. Genetic Disorders 13.16.3. Infectious diseases 13.16.4. Other Diseases 13.17. South Africa Viral Vector Manufacturing Markets Forecast, by Application 13.17.1. Gene Therapy 13.17.2. Vaccinology 13.17.3. Others 13.18. Rest of Middle East & Africa Viral Vector Manufacturing Markets Forecast, by Type 13.18.1. Retroviral Vectors 13.18.2. Adenoviral Vectors 13.18.3. Adeno-associated Viral Vectors 13.18.4. Other Viral Vectors 13.19. Rest of Middle East & Africa Viral Vector Manufacturing Markets Forecast, by Disease 13.19.1. Cancers 13.19.2. Genetic Disorders 13.19.3. Infectious diseases 13.19.4. Other Diseases 13.20. Rest of Middle East & Africa Viral Vector Manufacturing Markets Forecast, by Application 13.20.1. Gene Therapy 13.20.2. Vaccinology 13.20.3. Others 13.21. Middle East & Africa Viral Vector Manufacturing Markets Attractiveness Analysis 13.21.1. By Type 13.21.2. By Disease 13.21.3. By Application 13.22. PEST Analysis 14. Latin America Viral Vector Manufacturing Markets Analysis 14.1. Key Findings 14.2. Latin America Viral Vector Manufacturing Markets Overview 14.3. Latin America Viral Vector Manufacturing Markets Value Share Analysis, by Type 14.4. Latin America Viral Vector Manufacturing Markets Forecast, by Type 14.4.1. Retroviral Vectors 14.4.2. Adenoviral Vectors 14.4.3. Adeno-associated Viral Vectors 14.4.4. Other Viral Vectors 14.5. Latin America Viral Vector Manufacturing Markets Value Share Analysis, by Disease 14.6. Latin America Viral Vector Manufacturing Markets Forecast, by Disease 14.6.1. Cancers 14.6.2. Genetic Disorders 14.6.3. Infectious diseases 14.6.4. Other Diseases 14.7. Latin America Viral Vector Manufacturing Markets Value Share Analysis, by Application 14.8. Latin America Viral Vector Manufacturing Markets Forecast, by Application 14.8.1. Gene Therapy 14.8.2. Vaccinology 14.8.3. Others 14.9. Latin America Viral Vector Manufacturing Markets Value Share Analysis, by Country 14.10. Latin America Viral Vector Manufacturing Markets Forecast, by Country 14.10.1. Brazil 14.10.2. Mexico 14.10.3. Rest of Latin America 14.11. Latin America Viral Vector Manufacturing Markets Analysis, by Country/ Sub-region 14.12. Brazil Viral Vector Manufacturing Markets Forecast, by Type 14.12.1. Retroviral Vectors 14.12.2. Adenoviral Vectors 14.12.3. Adeno-associated Viral Vectors 14.12.4. Other Viral Vectors 14.13. Brazil Viral Vector Manufacturing Markets Forecast, by Disease 14.13.1. Cancers 14.13.2. Genetic Disorders 14.13.3. Infectious diseases 14.13.4. Other Diseases 14.14. Brazil Viral Vector Manufacturing Markets Forecast, by Application 14.14.1. Gene Therapy 14.14.2. Vaccinology 14.14.3. Others 14.15. Mexico Viral Vector Manufacturing Markets Forecast, by Type 14.15.1. Retroviral Vectors 14.15.2. Adenoviral Vectors 14.15.3. Adeno-associated Viral Vectors 14.15.4. Other Viral Vectors 14.16. Mexico Viral Vector Manufacturing Markets Forecast, by Disease 14.16.1. Cancers 14.16.2. Genetic Disorders 14.16.3. Infectious diseases 14.16.4. Other Diseases 14.17. Mexico Viral Vector Manufacturing Markets Forecast, by Application 14.17.1. Gene Therapy 14.17.2. Vaccinology 14.17.3. Others 14.18. Rest of Latin America Viral Vector Manufacturing Markets Forecast, by Type 14.18.1. Retroviral Vectors 14.18.2. Adenoviral Vectors 14.18.3. Adeno-associated Viral Vectors 14.18.4. Other Viral Vectors 14.19. Rest of Latin America Viral Vector Manufacturing Markets Forecast, by Disease 14.19.1. Cancers 14.19.2. Genetic Disorders 14.19.3. Infectious diseases 14.19.4. Other Diseases 14.20. Rest of Latin America Viral Vector Manufacturing Markets Forecast, by Application 14.20.1. Gene Therapy 14.20.2. Vaccinology 14.20.3. Others 14.21. Latin America Viral Vector Manufacturing Markets Attractiveness Analysis 14.21.1. By Type 14.21.2. By Disease 14.21.3. By Application 14.22. PEST Analysis 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.3. Company Profiles: Key Players 15.3.1. Virovek 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Business Strategy 15.3.1.4. Recent Developments 15.3.1.5. Manufacturing Footprint 15.3.2. Advanced Bioscience Laboratories, Inc. 15.3.3. Advanced Biotherapeutics Consulting 15.3.4. Applied Viromics 15.3.5. Batavia Biosciences 15.3.6. Benitec Biopharma 15.3.7. Biogen Idec (Now Biogen, Inc.) 15.3.8. Biovian 15.3.9. Boehringer Ingelheim Gmbh 15.3.10. Brammer Bio 15.3.11. Cell And Gene Therapy Catapult 15.3.12. Ceva Corporate 15.3.13. Cobra Biologics (Subsidiary Of Recip Ab) 15.3.14. Creative Biogene 15.3.15. GE Healthcare 15.3.16. Genedetect 15.3.17. Genvec Inc. (Subsidiary of Intrexon Corp.) 15.3.18. ID Pharma Co. Ltd. 15.3.19. Janssen Pharmaceutical Companies Of Johnson & Johnson 15.3.20. Lonza 15.3.21. Merck Millipore 15.3.22. Miltenyi Biotec 15.3.23. Molmed Spa 15.3.24. Paragon Bioservices Inc. 15.3.25. Pfizer Inc. 15.3.26. Sanofi 15.3.27. Sementis 15.3.28. Spark Therapeutics Inc. 15.3.29. Synpromics 15.3.30. Valneva 15.3.31. Vector Biolabs 15.3.32. Vigene Biosciences Inc. 16. Primary Key Insights

About This Report

Report ID21669
Category Biotechnology
Published DateAugust 2019
Updated Dateoct 2020
Contact Us